This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, To Reduce Hospital Readmissions

TRENTON, N.J. and WALTHAM, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- The Trenton Health Team (THT) and BG Medicine (Nasdaq:BGMD) today announced that THT has adopted the BGM Galectin-3® test throughout its organization to identify patients at near term risk for heart failure rehospitalization. THT is a community health improvement collaborative that serves the six zip codes of Trenton, New Jersey and is in the process of developing a Medicaid accountable care organization (ACO).

Reducing unplanned readmissions for patients continues to be one of the most urgent and pressing issues facing hospitals in the U.S. today, particularly since October 2012, when the federal Centers for Medicare & Medicaid Services (CMS) enacted new rules that impose significant financial penalties on hospitals with excessive 30-day hospital readmission rates. Among the heart failure population, hospital readmissions can approach up to 25% within 30 days, putting a substantial economic and emotional burden on patients and families, while costing the healthcare system billions of dollars.

"As a collaborative looking to develop an accountable care organization, we are always looking for products and programs that can deliver better quality healthcare while reducing overall costs. THT is committed to reducing unplanned hospital readmissions across the board by 15% in 2013, and the Galectin-3 diagnostic blood test should help us make an impact on readmission rates in one of the most costly patient populations—chronic heart failure patients," stated Dr. Robert Remstein, the President of THT and Vice President for accountable care at Capital Health. "This test can assist our urban based clinicians in identification of patients with heart failure at highest risk for poor outcomes, and guide them towards cost effective care that will improve outcomes and lower overall health care costs."

"Measuring Galectin-3 levels is a simple way to identify patients who are at higher risk of poor outcomes resulting from cardiovascular disease leading to unplanned readmission," stated Eric Bouvier, President and CEO of BG Medicine. "The Trenton Healthcare Team is leading the charge by adopting a broad scope of efforts to reduce costly hospital readmissions."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs